LKFT Lakefront Biotherapeutics - American Depositary Shares
NASDAQLKFT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
LKFT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Lakefront Biotherapeutics - American Depositary Shares Company overview from Wikipedia
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $0.03 | $-0.44 | 106.8% | |
| March 31, 2026 | $0.22 | $-0.52 | 142.7% | |
| Dec. 31, 2025 | $11.87 | $2.76 | 329.9% | |
| Sept. 30, 2025 | $-3.07 | $-0.02 | -19965.4% | |
| June 30, 2025 | $-1.60 | $-0.09 | -1681.7% | |
| March 31, 2025 | $11.87 | $2.76 | 329.9% |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 filings | July 28, 2025 | 13.22% | Amendment | · | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | Feb. 14, 2025 | 7.50% | Initial filing | Passive investment | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | Nov. 2, 2021 | · | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 18 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| EWK · iShares, Inc. | 0.64% | 39,355 SH | Sept. 11, 2026 | Daily |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.62% | 4,052 SH | Oct. 28, 2026 | Daily |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.09% | 10,229 SH | Oct. 28, 2026 | Daily |
| IBB · iShares Trust | 0.08% | 315,163 SH | Sept. 11, 2026 | Daily |
| IEUS · iShares Trust | 0.05% | 3,329 SH | Sept. 11, 2026 | Daily |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 188,173 SH | Aug. 19, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 1,194 SH | Oct. 28, 2026 | Daily |
| SCZ · iShares Trust | 0.02% | 103,401 SH | Sept. 11, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 2,569 SH | Sept. 11, 2026 | Daily |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 119,870 SH | Aug. 19, 2026 | Daily |
| IEUR · iShares Trust | 0.01% | 28,052 SH | Sept. 11, 2026 | Daily |
| IEFA · iShares Trust | 0.00% | 301,865 SH | Sept. 11, 2026 | Daily |
| IDEV · iShares Trust | 0.00% | 40,908 SH | Sept. 11, 2026 | Daily |
| IXUS · iShares Trust | 0.00% | 62,009 SH | Sept. 11, 2026 | Daily |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 717,158 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 36,160 SH | Aug. 19, 2026 | Daily |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.00% | 483,750 SH | Aug. 19, 2026 | Daily |
| VSGX · VANGUARD WORLD FUND | 0.00% | 9,595 SH | Aug. 19, 2026 | Daily |
LKFT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
3 analysts · 2026-10-24Mean target $30.44 -5.1%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LKFT | · | · | · | · | · | · |
| MDXH | · | -5.3 | · | -31.1% | -2440.4% | 64.5% |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.